LCTX
Lineage Cell Therapeutics Inc
NYSE MKT: LCTX · HEALTHCARE · BIOTECHNOLOGY
$1.43
-2.05% today
Updated 2026-05-06
Market cap
$363.98M
P/E ratio
—
P/S ratio
25.01x
EPS (TTM)
$-0.28
Dividend yield
—
52W range
$0 – $2
Volume
1.2M
Lineage Cell Therapeutics Inc (LCTX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-99.10%
ROE
-105.30%
ROA
-12.10%
Debt/equity
0.12x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.16M | $-1.86M | 100.00% | -150.76% | -160.46% |
| 2007 | $1.05M | $-1.44M | 100.00% | -116.85% | -137.48% |
| 2008 | $1.50M | $-3.78M | 100.00% | -187.70% | -251.42% |
| 2009 | $1.93M | $-5.14M | 100.00% | -182.86% | -267.19% |
| 2010 | $3.68M | $-11.18M | 100.00% | -267.70% | -303.91% |
| 2011 | $4.35M | $-16.52M | 100.00% | -429.10% | -379.25% |
| 2012 | $1.69M | $-21.43M | 74.35% | -1,476.82% | -1,265.64% |
| 2013 | $2.86M | $-43.88M | 72.29% | -1,956.83% | -1,533.82% |
| 2014 | $1.95M | $-36.41M | 56.99% | -2,603.95% | -1,870.75% |
| 2015 | $2.53M | $-46.99M | 56.31% | -2,597.04% | -1,854.42% |
| 2016 | $2.25M | $33.57M | 84.10% | -2,618.43% | 1,490.76% |
| 2017 | $1.79M | $-19.98M | 90.63% | -2,170.87% | -1,114.73% |
| 2018 | $1.42M | $-45.99M | 78.67% | -2,951.62% | -3,247.88% |
| 2019 | $1.48M | $-11.71M | 72.12% | -2,630.31% | -792.22% |
| 2020 | $773000.00 | $-20.65M | 50.19% | -3,421.35% | -2,671.28% |
| 2021 | $3.90M | $-43.02M | 63.40% | -1,263.12% | -1,104.18% |
| 2022 | $14.70M | $-26.27M | 95.05% | -153.17% | -178.69% |
| 2023 | $8.95M | $-21.49M | 92.50% | -276.50% | -240.20% |
| 2024 | $9.50M | $-18.61M | 96.48% | -226.11% | -195.90% |
| 2025 | $14.56M | $-63.53M | 94.19% | -149.62% | -436.47% |